These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

723 related items for PubMed ID: 21220152

  • 1. Clinical efficacy of a novel VWF-containing FVIII concentrate, Wilate(®), in the prophylaxis and treatment of bleeding episodes in previously treated haemophilia A patients.
    Klukowska A, Windyga J, Batorova A.
    Thromb Res; 2011 Mar; 127(3):247-53. PubMed ID: 21220152
    [Abstract] [Full Text] [Related]

  • 2. Treatment and prevention of acute bleedings in von Willebrand disease--efficacy and safety of Wilate, a new generation von Willebrand factor/factor VIII concentrate.
    Berntorp E, Windyga J, European Wilate Study Group.
    Haemophilia; 2009 Jan; 15(1):122-30. PubMed ID: 19149848
    [Abstract] [Full Text] [Related]

  • 3. Safety and efficacy of a von Willebrand factor/factor VIII concentrate (Wilate®): a single centre experience.
    Batty P, Chen YH, Bowles L, Hart DP, Platton S, Pasi KJ.
    Haemophilia; 2014 Nov; 20(6):846-53. PubMed ID: 25102895
    [Abstract] [Full Text] [Related]

  • 4. Efficacy and safety of a new generation von Willebrand factor/factor VIII concentrate (Wilate®) in the management of perioperative haemostasis in von Willebrand disease patients undergoing surgery.
    Windyga J, von Depka-Prondzinski M, European Wilate® Study Group.
    Thromb Haemost; 2011 Jun; 105(6):1072-9. PubMed ID: 21437358
    [Abstract] [Full Text] [Related]

  • 5. Efficacy and safety of Wilate in paediatric VWD patients under 6 years of age - results of a prospective multicentre clinical study including recovery information.
    Nowak-Göttl U, Krümpel A, Russo A, Jansen M.
    Haemophilia; 2013 Nov; 19(6):887-92. PubMed ID: 23919249
    [Abstract] [Full Text] [Related]

  • 6. Low incidence of factor VIII inhibitors in previously untreated patients during prophylaxis, on-demand treatment and surgical procedures, with Octanate®: interim report from an ongoing prospective clinical study.
    Klukowska A, Komrska V, Jansen M, Laguna P.
    Haemophilia; 2011 May; 17(3):399-406. PubMed ID: 21118334
    [Abstract] [Full Text] [Related]

  • 7. The clinical efficacy and safety of the FVIII/VWF concentrate, BIOSTATE®, in children with von Willebrand disorder: a multi-centre retrospective review.
    Howman R, Barnes C, Curtin J, Price J, Robertson J, Russell S, Seldon M, Suppiah R, Teague L, Barrese G.
    Haemophilia; 2011 May; 17(3):463-9. PubMed ID: 21118340
    [Abstract] [Full Text] [Related]

  • 8. Efficacy and safety of the factor VIII/von Willebrand factor concentrate, haemate-P/humate-P: ristocetin cofactor unit dosing in patients with von Willebrand disease.
    Lillicrap D, Poon MC, Walker I, Xie F, Schwartz BA, Association of Hemophilia Clinic Directors of Canada.
    Thromb Haemost; 2002 Feb; 87(2):224-30. PubMed ID: 11858481
    [Abstract] [Full Text] [Related]

  • 9. Clinical efficacy and safety of the factor VIII/von Willebrand factor concentrate BIOSTATE in patients with von Willebrand's disease: a prospective multi-centre study.
    Dunkley S, Baker RI, Pidcock M, Price J, Seldon M, Smith M, Street A, Maher D, Barrese G, Stone C, Lloyd J.
    Haemophilia; 2010 Jul 01; 16(4):615-24. PubMed ID: 20331755
    [Abstract] [Full Text] [Related]

  • 10. Clinical efficacy in bleeding and surgery in von Willebrand patients treated with Fanhdi a highly purified, doubly inactivated FVIII/VWF concentrate.
    Hernandez-Navarro F, Quintana M, Jimenez-Yuste V, Alvarez MT, Fernandez-Morata R.
    Haemophilia; 2008 Sep 01; 14(5):963-7. PubMed ID: 18624696
    [Abstract] [Full Text] [Related]

  • 11. Efficacy and safety of a VWF/FVIII concentrate (wilate® ) in inherited von Willebrand disease patients undergoing surgical procedures.
    Srivastava A, Serban M, Werner S, Schwartz BA, Kessler CM, Wonders Study Investigators.
    Haemophilia; 2017 Mar 01; 23(2):264-272. PubMed ID: 28026130
    [Abstract] [Full Text] [Related]

  • 12. Efficacy and safety of factor VIII/von Willebrand's factor concentrate (Haemate-P) in preventing bleeding during surgery or invasive procedures in patients with von Willebrand disease.
    Franchini M, Rossetti G, Tagliaferri A, Pattacini C, Pozzoli D, Lippi G, Manzato F, Bertuzzo D, Gandini G.
    Haematologica; 2003 Nov 01; 88(11):1279-83. PubMed ID: 14607757
    [Abstract] [Full Text] [Related]

  • 13. Efficacy, safety and pharmacokinetic profiles of a plasma-derived VWF/FVIII concentrate (VONCENTO®) in subjects with haemophilia A (SWIFT-HA study).
    Skotnicki A, Lissitchkov TJ, Mamonov V, Buevich E, Kuliczkowski K, Goranov S, Kłoczko J, Klukowska A, Stankovic S, Gercheva L, Chernova T, Hellmann A, Dmoszyńska A, Zawilska K, Veldman A, Joch C, Seifert W.
    Thromb Res; 2016 Jan 01; 137():119-125. PubMed ID: 26614676
    [Abstract] [Full Text] [Related]

  • 14. The pharmacokinetic diversity of two von Willebrand factor (VWF)/ factor VIII (FVIII) concentrates in subjects with congenital von Willebrand disease. Results from a prospective, randomised crossover study.
    Kessler CM, Friedman K, Schwartz BA, Gill JC, Powell JS, Wilate PK Study Investigators.
    Thromb Haemost; 2011 Aug 01; 106(2):279-88. PubMed ID: 21725579
    [Abstract] [Full Text] [Related]

  • 15. Fanhdi, efficacy and safety in von Willebrand's disease: prospective international study results.
    Bello IF, Yuste VJ, Molina MQ, Navarro FH.
    Haemophilia; 2007 Dec 01; 13 Suppl 5():25-32. PubMed ID: 18078394
    [Abstract] [Full Text] [Related]

  • 16. Efficacy and safety during formulation switch of a pasteurized VWF/FVIII concentrate: results from an Italian prospective observational study in patients with von Willebrand disease.
    Castaman G, Coppola A, Zanon E, Boeri E, Musso M, Siragusa S, Federici AB, Mancuso G, Barillari G, Biasoli C, Feola G, Franchini M, Moratelli S, Gamba G, Schinco P, Valdrè L, Dragani A, Mazzucconi G, Tagliaferri A, Morfini M.
    Haemophilia; 2013 Jan 01; 19(1):82-8. PubMed ID: 22957493
    [Abstract] [Full Text] [Related]

  • 17. Intravenous DDAVP and factor VIII-von Willebrand factor concentrate for the treatment and prophylaxis of bleedings in patients With von Willebrand disease type 1, 2 and 3.
    Michiels JJ, van Vliet HH, Berneman Z, Gadisseur A, van der Planken M, Schroyens W, van der Velden A, Budde U.
    Clin Appl Thromb Hemost; 2007 Jan 01; 13(1):14-34. PubMed ID: 17164493
    [Abstract] [Full Text] [Related]

  • 18. A systematic overview of the first pasteurised VWF/FVIII medicinal product, Haemate P/ Humate -P: history and clinical performance.
    Berntorp E, Archey W, Auerswald G, Federici AB, Franchini M, Knaub S, Kreuz W, Lethagen S, Mannucci PM, Pollmann H, Scharrer I, Hoots K.
    Eur J Haematol Suppl; 2008 May 01; (70):3-35. PubMed ID: 18380871
    [Abstract] [Full Text] [Related]

  • 19. Use of Haemate(®) P as immune tolerance induction in patients with severe haemophilia A who failed previous induction attempts: a multicentre observational study.
    Rothschild C, D'Oiron R, Borel-Derlon A, Gruel Y, Navarro R, Negrier C.
    Haemophilia; 2013 Mar 01; 19(2):281-6. PubMed ID: 23038998
    [Abstract] [Full Text] [Related]

  • 20. Evaluation of pharmacokinetics, efficacy and safety of Immunate solvent detergent in previously treated patients with severe haemophilia A.
    Nemes L, Lissitchkov T, Klukowska A, Dobaczewski G, Komrska V, Zimmermann R, Auerswald G, Engl W, Pavlova B, Abbühl B, Ehrlich HJ.
    Haemophilia; 2007 Jan 01; 13(1):9-11. PubMed ID: 17212718
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 37.